Diligence memo · auto-generated · as of July 2, 2026
Phase Genomics, Inc.
Phase Genomics, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Phase Genomics, Inc. operates in Biotechnology, based in SEATTLE.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Phase Genomics, Inc. has raised $5.8M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.8M on 2023-03-14.
Most recent recorded round closed around 2023-03-14.
Valuation (modeled)modeled
Provath models Phase Genomics, Inc. at approximately $47M (range $5.2M–$137M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.05× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 64 months.
Last raise 3.3 yr ago; this sector typically re-raises about every 14 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 4.8× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 46% of Biotechnology peers (4293 compared).
Modeled value ranks above 44% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.